Migraine is known to be one of the three most prevalent diseases in the world and the disease is prevalent in around 14% of the entire world population. In the US, the prevalence of Migraine is around 12% of the US population.
The report gives the overview of Migraine disease indication in detail and highlights the Migraine epidemiology split into Episodic and Chronic Migraine in the present scenario and in future (forecasted) as well in the key geographies across the globe.
The report starts with the basic definition, causes and symptoms of Migraine and further details the types of Migraine disease indication. The report covers further details on the profile of an Migraine patient, Symptoms of Migraine patient, and disease progression in a Migraine patient. The report further highlights the multiple methods through which the patient can be diagnosed for Migraine.
The later part of the report consists of Migraine epidemiology and prevalence split into Episodic and Chronic Migraine in the key geographies across the globe like US, UK, Germany, Italy, France, Spain, Japan etc. The epidemiology for Migraine indication across key geographies has been forecasted till 2024 as well in the report.
Migraine Definition
Classification of Migraine based on symptoms and severity and based on frequency of attacks
Causes of Migraine
Profile of Migraine patient
Symptoms of Migraine patient
Disease progression and impact on QoL
Disease diagnosis
Disease Epidemiology in key markets including Episodic and Chronic Migraine split
Teva
Novartis
Amgen
Allergan
Alder
Eli Lilly
Pfizer
Glaxo Smithkline
Briston Mayers
Allodynic Therapeutics
Pharmalyte Solutions
Ionis Pharmaceuticals
Helsinn Group
Otsuka Holdings
NeurAxon Inc.
Achelios Therapeutics
Trigemina
